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012.04.00Abstract Aim of the work: The present study was undertaken to assess prevalence and character-
istics of peripheral neuropathy (PN) in Egyptian hepatitis C virus (HCV) patients.
Patients and methods: Eighty newly diagnosed HCV patients were enrolled, with 20 healthy
volunteers. All were subjected to: full clinical examination, neurological examination, laboratory
assessment including; routine blood tests, ESR, CRP, RF, ANA, C4, cryoglobulins (CGs), anti-
GM1 antibodies, HCV antibodies, Quantitative PCR, abdominal ultrasonography, liver biopsy,
and electrophysiological assessment.
Results: Thirty-six patients (45%) had clinical neuropathy, 18 patients (22.5%) had subclinical
neuropathy. Thirty-eight out of the 54 PN patients (70.3%) showed axonal neuropathy which is
mainly sensory affecting lower limbs. Twelve patients showed +ve cryoglobulinemia, all of them
had neuropathy (10 clinical, 2 subclinical). Abnormal titers of anti-neuronal antibodies were associ-lty of Medicine, Elgesh Street,
264626.
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92 M. Aly Abdel Khalek et al.ated with electrophysiological abnormalities in 50 out of the 54 PN patients. PN correlated with age,
disease duration, ESR, CRP, RF, HCV viraemia, CGs, anti-GM1 and hypocomplementinemia.
Conclusions: PN exists in high prevalence among Egyptian HCV patients, and is associated with
CG. It is mainly of axonal sensory type more affecting lower limbs. HCV patients should be investi-
gated for the presence of CGs even in the absence of clinical manifestations.
 2012 Egyptian Society for Joint Diseases and Arthritis.
Open access under CC BY-NC-ND license.1. Introduction
Hepatitis C virus (HCV) is a parenterally transmitted, hepato-
tropic, and lymphotropic RNA virus. More than 170 million
people worldwide are chronically infected with HCV [1]. In
high endemic areas such as Egypt and southern Italy local
prevalence may reach 30% [2]. In Egypt genotype 4 constitutes
73.3% of all HCV positive cases [3]. HCV infection is the most
common cause of chronic liver disease, accounts for 50% of all
primary liver cancers [4].
HCV viremia has been known to provoke a plethora of
autoimmune syndromes which has been referred to as extrahe-
patic manifestations (EHMs) which affect 40–70% of patients
of chronic HCV infection mainly mixed cryoglobulinaemia
(MCG) [5–7]. 50% to 80% of patients with essential MCG
are infected with HCV and up to 50% of patients with hepati-
tis C infection have MCG [8]. In HCV/MCG patients, clinical
involvement is mainly characterized by purpura, arthralgias,
kidney disease, and peripheral neuropathy (PN) [9].
Neurological complications in HCV-infected patients occur
predominantly in the peripheral nervous system (PNS). Their
prevalence varies, and can be as high as 50% of cases and is
primarily associated with MCG [10]. PNS involvement has
also been reported in HCV-infected patients without MCG
[11,12].
The pathophysiology of HCV related PN remains largely
speculative; vascular deposition of HCV-RNA containing cry-
oglobulins (CGs), direct viral infection or perivascular mono-
nuclear inﬂammatory cells may be at the origin of HCV
associated inﬂammatory vascular lesions. However, it is likely
that HCV neuropathy results from virus triggered immune
mediated mechanisms rather than from direct nerve infection
and in situ replication [13].
Recent evidence suggests that direct autoantibody reactions
may play at least an additional role in affecting neuronal struc-
tures [14]. Within humoral autoimmunity to neuronal anti-
gens, serum anti-ganglioside antibodies have been found in
several central and peripheral neurological diseases and auto-
immune disorders [15].
Gangliosides which are localized to the surface of central
and peripheral neurones and exert a pivotal role in a variety
of cell-surface mediated functions, include a wide array of
molecules referred to as GM1, GM2, GD1a, GD1b, GT1b
and GQ1b [16].
Many studies have reported various types of PN in western
countries and Egypt [17–19,33]. The present study was under-
taken to shed the light on prevalence and the characteristics of
PN in a sample of Egyptian HCV patients and its possible
correlations through clinical, laboratory and electrophysiolog-
ical assessments.2. Patients and methods
This study was carried out on 80 newly diagnosed, treatment-
naı¨ve HCV infection patients (48 males & 32 females) with
mean age of 40.08 ± 7.29 years. Patients were selected from
those being evaluated for antiviral therapy at the outpatient
clinics of the Tropical Medicine department, Tanta University
Hospitals, Egypt. In addition, twenty age and sex matched
healthy volunteers were enrolled as control group.
2.1. Inclusion criteria
1. HCV-RNA positive patients by polymerase chain reac-
tion (PCR).
2. The patients did not receive any treatment for HCV
infection.
2.2. Exclusion criteria
(a) Other diseases associated with neuropathy such as
diabetes mellitus (abnormal HbA1c and fasting glucose
test prior to enrollment), autoimmune disorder, renal
failure, thyroid disorders, malignant hematological dis-
orders, alcohol consumption (drinking low percentage
alcohol beverages more frequently than once per week),
HIV infection or drug addiction.
(b) Impairment of the PNS other than neuropathy (e.g. tun-
nelopathies, radiculopathies, and nerve trauma).
(c) Impairment of central sensory pathways (e.g. multiple
sclerosis).
All patients gave an informed consent for a study. Patients
were evaluated clinically, serologically, and electrophy-
siologically.
2.3. Clinical examination
Patients and control subjects were subjected to general exami-
nation with a special attention to hepatic & EHMs of HCV
infection in patients. A diagnosis of clinical neuropathy was
made when symptoms (weakness, sensory disturbances) and
signs (weakness, atrophy, sensory abnormalities and/or re-
duced/absent tendon reﬂexes) of peripheral sensory and/or
motor and cranial involvement were present. Self completed
Leeds assessment of neuropathic symptoms and signs (S-
LANSS) questionnaire was used as a diagnostic tool for neuro-
pathic pain, on the scale, patients were asked how bad his pain
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means pain as severe as it could be [20].
2.4. Serological studies
Laboratory studies include, routine blood tests, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), alanine
aminotransferase (ALT), aspartate aminotransferase (AST),
IgM rheumatoid factor (RF), complement-4(C4) values, anti-
nuclear antibody (ANA), detection and characterization of
CGs according to Vermeersch et al. [21].
Anti-HCV antibodies were detected by third generation en-
zyme linked immunosorbent assay (ELIZA) (Roche Diagnos-
tics, Mannheim, Germany) [22].
Quantitative HCV RNA test is based on the polymerase
chain reaction (PCR) technique using a commercial kit
(HEPA-Check-C, Nuclear Laser Medicine, Italy) and has a
lower limit of detection of fewer than 100 copies of HCV
RNA per ml of serum (50 IU/ml). It was classiﬁed into weak
(100–100.000), moderate (100.000–1000.000) and high
(>1000.000) [23].
Anti-neuronal antibodies measurement: Anti-GM1 antibod-
ies were measured by enzyme-linked immunoassay (ELISA).
The microtiter plates were precoated with monosialo-ganglio-
side GM. All the samples were diluted 50 times with a buffer
saline solution and 100 ml diluted samples were pipetted into
the wells (incubation buffer in blank). The plate was incubated
for 2 h at 2–8 C and after discarding the contents the wells
were washed thrice with refrigerated wash buffer. Then
100 ml enzyme conjugated to horseradish peroxidase labeled
antibody directed against IgG and IgM was added and incu-
bated for 2 h at 2–8 C. After washing the wells thrice with
wash buffer, 100 ml of tetramethylbenzidine substrate (TMB)
(allowed to come to ambient temperature prior to use) was
added to each well. The plate was covered properly to protect
from light and incubated for 30 min at room temperature on a
plate mixture with 800–1000 rpm. The reaction was stopped by
100 ml of 0.25 M H2 SO4 and the absorbance was read at
450 nm. Antibody titers were calculated from optical densities
(OD) as previously described by Pestronk [24]. Positivity cut-
off titer was set at 1:400 for both IgM and IgG [25].
2.5. Abdominal ultrasonography
Abdominal ultrasonography was performed for patients only,
where liver ﬁbrosis was evaluated by ultrasound scoring system
which ranges from 4 for a normal liver to 9 or more for
advanced cirrhosis [26].
2.6. Liver biopsy
Liver specimens were obtained from patients for histopatholo-
gical examination to conﬁrm diagnosis, to exclude other
causes, to determine the stage of ﬁbrosis and grade of inﬂam-
mation using modiﬁed Knodell score [27].
2.7. Electrophysiological techniques
The electrophysiological studies were performed in the electro-
physiology unit, in the Rheumatology & Rehabilitation
Department, Tanta University Hospitals, Egypt, using The Ni-
hon Kohden Neuropack 2 (Nihon Kohden, Japan). Surfacetemperature was maintained at 31–33 C, the ampliﬁer settings
were at 10–2000 Hz. Nerve conduction studies were performed
bilaterally according to a standardized protocol using surface
electrodes as follows: motor conduction study of median, ul-
nar, posterior tibial and peroneal nerves, minimal F wave
latencies of median, ulnar and posterior tibial nerves, soleus
H reﬂex study and sensory conduction study using antidromic
stimulation of median (digit II), ulnar (digit V), radial (The
active electrode was placed over the tendon of the extensor
pollicis longus muscle, stimuli were applied 10 cm proximal
to the active electrode over the radius.) and sural nerves
(lateral malleolus to 12 cm just lateral from the midline of
the calf). Sural/radial nerve amplitude ratio (SRAR) was cal-
culated by dividing the highest sural nerve amplitude by the
highest superﬁcial radial nerve amplitude.
Parameters were considered abnormal when they differed
from the mean by ±2.0 SD obtained from the control group.
Patients were considered to have clinical neuropathy when
they had one or more electrophysiological abnormalities in
at least two nerves examined and it considered subclinical
when they have electrophysiologic abnormalities with no clin-
ical symptoms and signs of peripheral nerve involvement.
Statistical analysis: All data were analyzed using software
(version 11, SPSS Inc., Chicago, Illinois). All data were pre-
sented as mean ± standard deviation for the continuous vari-
ables, and as frequency and percentage for the discrete ones.
Independent ‘‘t’’ test was used for when comparison between
two groups was needed. Correlation between variables was
examined using the Pearson’s correlation coefﬁcient. P value
<0.05 was considered statistically signiﬁcant. Sensitivity was
calculated for latency of H-reﬂex and SRAR.3. Results
Eighty HCV patients were enrolled in this study, 48 males and
32 females, their ages ranged from 28 to 50 years. Control
group, included 13 males and 7 females, their ages ranged from
28 to 48 years. All the patients were accidentally discovered
and the cause of disease transmission was unknown, duration
since discovery of HCV infection ranged from 3 to 30 months.
ESR, CRP, RF, and ANA were signiﬁcantly higher in patients
than in controls (p< 0.01), while C4 was signiﬁcantly lower
in HCV patients (p< 0.01). Other laboratory parameters
showed statistically signiﬁcant difference between patients
and controls including serum transaminases (p< 0.001) and
anti-neuronal antibodies (p< 0.001). Detectable CGs (with a
cryocrit greater than 0.1%) were found in 15% of patients.
The main demographic, and laboratory features of patients
and control group are shown in Table 1.
Quantitative PCR revealed that the majority of our patients
(55%) had moderate viraemia, 30% had weak viraemia and
15% had high viraemia. Ultrasound scoring system of liver
ﬁbrosis showed that 87.5% of our patients had mild to moder-
ate ﬁbrosis, 12.5% had no ﬁbrosis; while none of them had
severe ﬁbrosis.
The histological activity grading (HAI) demonstrated that
55% of the patients have minimal inﬂammation (score 1–4),
while, 35% of them have mild inﬂammation (score 5–8) and
10% of them have moderate inﬂammation (score 9–12). On
the other hand, staging of liver ﬁbrosis (modiﬁed Knodells
score) revealed that 50% of the patients had score 1 of ﬁbrosis,
Table 1 Demographic and serological data of HCV patients and controls.
Parameters HCV patients (n= 80) Controls (n= 20)
Age 40.08 ± 7.29 37.00 ± 5.94
Sex (M/F) 48/32 13/7
Duration since disease discovery/months 14.60 ± 10.29 –
ESR (mm/h) 19.82 ± 7.89* 12.53 ± 6.88
CRP (mg/dl) 6.30 ± 4.4* 4.400 ± 0.73
RF (mg/dl) 121 ± 80* 7.20 ± 1.52
ANA (U/ml) 12.51 ± 2.8* 5.32 ± 1.7
C4 (mg/dl) 13.85 ± 6.5* 21.49 ± 9.7
ALT (U/l) 51.3 ± 40.2** 23.8 ± 8.69
AST (U/l) 54.1 ± 40.3** 20.07 ± 6.5
CG+ve patients (n &%) 12 (15%) –
IgM anti-GM1 titer 1:570 ± 1:400** 1:170 ± 1:167
IgG anti-GM1 titer 1:537 ± 1:409** 1:200 ± 1:100
HCV: Hepatitis C virus; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ALT: alanine aminotransferase; AST: aspartate
aminotransferase; RF: rheumatoid factor; C4: complement-4; ANA: anti-nuclear antibody; CG: cryoglobulin; anti-GM1: anti-ganglioside
antibodies.
* <0.01 compared to controls.
** <0.001 compared to controls.
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of ﬁbrosis, 5% of them had score 4 of ﬁbrosis and 5% of them
have incomplete cirrhosis (score 5).
Neurological examinations are showed in Table 2. Clinical
PN was diagnosed in 36 out of 80 patients (45%). All of them
had electrophysiological evidence of PN. Moreover, electro-
physiological examination disclosed a subclinical PN in 18
additional patients (22.5%). Totaly, 54 of our patients
(67.5%) were diagnosed to have neuropathy by electrophysio-
logical examination.
Electrophysiological studies showed axonal neuropathy in
38 patients out of the 54 neuropathy patients (70.3%) which
was mainly sensory affecting lower limbs (Table 3). Mean-
while, 29.7% of them showed mixed axonal and demyelinating
sensorimotor polyneuropathy; sensory and motor nerves in the
lower limbs were involved predominantly and sensory nerves
were more affected than motor nerves. In the lower limbs,
MCVs were reduced in 14 patients, reduction of CMAP ampli-
tude in 40 patients, abnormal F wave latency in 20 patients
and abnormal H-reﬂex in 40 patients. In the upper limbsTable 2 Clinical neurological data in HCV patients.



























All data were presented as frequency and percentage. HCV: Hep-
atitis C virus; S-LANSS: Leeds assessment of neuropathic symp-
toms and signs.MCVs were reduced in 6 patients, reduction of amplitude in
14 patients and abnormal F wave latency in 16 patients. SNPs
of sural nerve were absent in 5 patients, abnormal amplitude
and velocities in 30 patients and abnormal SRSR amplitude
in 40 patients. In the upper limbs SCVs reduced in 8 patients.
Sensitivity of H reﬂex and SRAR in HCV patients is the
same (55.5%) but combination of both tests increased sensitiv-
ity to 94.4%.
There was signiﬁcant correlation between most of nerve
conduction parameters with age of the patients, disease dura-
tion, ESR, CRP, RF, and IgM & IgG anti-GM1, load of
viraemia and CG (p< 0.001). All of our CG+ patients had
PN (10 clinical, 2 subclinical). Moreover, there was signiﬁcant
negative correlation between nerve conduction parameters with
level of C4. Nevertheless, there was no signiﬁcant correlation
between nerve conduction parameters with staging of liver
ﬁbrosis either by ultrasound scoring system or modiﬁed
Knodells score.
Abnormal titers of anti-neuronal antibodies were found to
be associated with electrophysiological abnormalities in 50 out
of the 54 neuropathy cases.4. Discussion
The population of Egypt has a heavy burden of liver disease,
mostly due to chronic HCV infection. The overall prevalence
of antibody to HCV in the general population is around
15–20% [28]. The majority of the literature reporting on the
neurological manifestations of HCV patients points to the
PNS and describes painful neuropathies [29]. Antibodies
against several neural antigens have been associated with a
number of chronic immune-mediated neuropathies [30]. Detec-
tion of these anti-neuronal antibodies might provide additional
prognostic insights and suggest a new scenario of the patho-
genesis of the neurological manifestations of HCV related
MCG [14].
In the current study, 70% of our patients were over 40 years
which agrees with Frank et al. [28] who reported increased
prevalence of HCV with age, and they explained it by the
possibility of exposure of these groups to schistosomiasis
Table 3 Motor and sensory nerve conduction studies in HCV patients and controls.
Electrophysiological parameters Hepatitis C patients Controls (n= 20)
Median motor nerve (n = 80)
MCV (m/s) 55.43 ± 6.0 58.29 ± 8.3
DL (ms) 3.95 ± 0.45 3.78 ± 0.29
Amp (mV) 4.24 ± 2.28* 6.88 ± 2.77
F wave (ms) 26.5 ± 4.87 26.83 ± 1.6
Ulnar motor nerve (n = 80)
MCV (m/s) 57.1 ± 7.49 56.4 ± 5.95
DL (ms) 2.93 ± 0.51 2.79 ± 0.48
Amp (mV) 4.21 ± 2.91* 7.26 ± 1.60
F wave (ms) 25.66 ± 6.59 26.77 ± 2.6
Peroneal nerve (n = 80)
MCV (m/s) 46.0 ± 6.25* 51.67 ± 4.3
DL (ms) 3.97 ± 0.83* 3.3 ± 0.144
Amp (mV) 2.87 ± 1.88* 6.55 ± 1.18
Posterior tibial nerve (n = 80)
MCV (m/s) 44. 1 ± 5.1* 48.9 ± 2.83
DL (ms) 4.66 ± 1.12* 3.17 ± 0.78
Amp (mV) 5.21 ± 3.33* 8.11 ± 3.01
F wave (ms) 48.65 ± 9.68* 45.28 ± 2.7
H-reﬂex (ms) 31.2 ± 5.96* 29.11 ± 0.9
Median sensory nerve (n = 80)
W-F SCV (m/s) 50.69 ± 5.38 52.36 ± 7.06
SAP ampl. (mcV) 21.3 ± 10.4 26.1 ± 15.6
Ulnar sensory nerve (n = 80)
W-F SCV (m/s) 58.73 ± 5.43 57.52 ± 8.19
SAP ampl. (mcV) 12.82 ± 9.96* 23.6 ± 10.9
Radial sensory nerve (n = 80)
W-F SCV (m/s) 54.27 ± 8.43 57.02 ± 3.88
SAP ampl. (mcV) 21.4 ± 10.7 22.99 ± 4.16
Sural nerve (n = 75)
SCV (m/s) 44.4 ± 11.8* 51.38 ± 5.09
SAP ampl. (mcV) 6.26 ± 4.43* 14.77 ± 3.14
S/R amplitude ratio 0.31 ± 0.21* 0.640 ± 0.13
MCV: motor conduction velocity; SCV: sensory conduction velocity, DL = distal latency; Amp: amplitude of compound motor action
potential or sensory action; SRAR: Sural/Radial nerve amplitude ratio.
* Statistically signiﬁcant <0.001 compared to controls.
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syringes during campaigns.
The majority of our patients was males (60%). Habib et al.
[31], revealed that the HCV is more prevalent in males than
females in Egypt due to the existence of two common potential
HCV exposures for males: (1) shaving by a community barber
using the same razor blade and (2) smoking tobacco with a
water pipe (Shisha) which can theoretically result in exposure
to blood from individuals with gingivitis.
PN was clinically diagnosed in 45% out of our patients,
42.5% showed sensory PN. The predominance of sensory
PN among our patients agrees with Sterling and Bralow [32],
who demonstrated that sensory deﬁciencies are more common
than motor loss, and that sensory symptoms may persist for
months to years before any motor deﬁcit become clinically evi-
dent. On the other hand, the high prevalence of clinical PN
among our patients is close to that reported by Cacoub et al.
[10], which was up to 50%. Meanwhile, it was not consistent
with previous Egyptian studies. The highest prevalence of
PN among Egyptian HCV patients was 30% reported by AbulHassan et al. [33], followed by 15.63% in the study of
El Ghoneimy et al. [19] and 10% in the study of Abo Al-Soud
et al. [34]. In western countries, Gomes et al. [35] reported PN
prevalence of 34.6%, while other studies reported prevalence
up to 10.6% [7,13,36].
This wide variability of PN prevalence among different
studies can be attributed to the model of patient enrollment,
which in our study was based on the presence of HCV infec-
tion in untreated patients, independently of the signs or symp-
toms. It also can be attributed to the use of different methods
for PN clinical evaluation.
It was mentioned that pure clinical assessment tends to
underestimate PNS involvement in the HCV population [13]
and that symptoms alone have relatively poor diagnostic accu-
racy in predicting the presence of PN and stressed on the
importance of electrodiagnosis for its diagnosis [37]. We
conﬁrmed this statement when electrophysiological examina-
tion of our patients disclosed a subclinical PN in 18 additional
patients (22.5%). This is in keeping with some authors who
diagnosed subclinical PN in their patients [13,34], and
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lence of clinical and electrophysiological PN, and with Gomes
et al. [35] who found clinical PN to be more than electrophys-
iological PN.
In the current study, a total of 67.5% (54/80) of our pa-
tients were diagnosed to have PN by electrophysiological
examination. This ﬁnding disagrees with many authors where
their percentage ranged from 8% to 37% [13,34–36,38,39].
Out of the 54 neuropathy patients, 38 patients (70.3%)
showed axonal neuropathy which was mainly sensory affecting
lower limbs more than upper limbs. While 16 patients (29.7%),
showed mixed axonal and demyelinating sensorimotor poly-
neuropathy; with the same distribution and predominance of
sensory affection. This ﬁnding is in accordance with some
authors who demonstrated axonal type of neuropathy among
their HCV patients with distal sensory or sensory-motor affec-
tion [7,33] or multifocal mononeuropathy. The underlying
pathogenetic mechanisms for this complication are systemic
CG and vasculitis [11,12,34,36,40–44]. Peripheral demyelinat-
ing neuropathy has been rarely described, most often in
CGve patients and results from the heterogeneity of the
pathophysiological mechanisms of neuropathies [11,42,45–47].
It has been hypothesized that SRAR can be used for the
detection of early axonal loss; because the sural SNAP ampli-
tude will decrease ﬁrst, thereby also decreasing the SRAR
value [48]. Our study showed that sensitivity of H-reﬂex and
SRAR HCV patients was the same (55.5%) but combination
of both tests increased sensitivity to 94.4%. This agrees with
the study by Kim et al. [49] Moreover, Rutkove et al. [50]
reported that an SRAR of less than 0.40 was a strong predictor
of axonal polyneuropathy, with 90% sensitivity and 90% spec-
iﬁcity, as compared to absolute sural amplitude which had
sensitivity of only 66%.
The big variation of PN prevalence in HCV patients among
different studies may be due to the fact that, it is a multifacto-
rial disease process. Ripault et al. [36] suggested that the most
important factor is the viral factors such as, viral genotypes as
there is wide difference between the viral genotypes in Egypt
and western countries.
15% of our patients showed positive CGs, which is very
close to the ﬁndings of Gad et al. [51], who reported CGs prev-
alence of 14% among HCV genotype 4 Egyptian patients.
While, this ﬁnding disagrees with many authors who reported
CG prevalence ranging from 19% up to 54% among their
HCV patients [7,52–55], and with Persico et al. [56] and
Verbaan et al. [57], who demonstrated 0.8% and 0% preva-
lences of CG in their patients consecutively.
The low prevalence of CGs among our HCV population
can be attributed to: (a) HCV genotype 4 which is the common
type among Egyptian patients is associated with low preva-
lence of CG compared to high prevalence in Japanese patients
infected with genotype 1b [51], and to HCV genotype 2a in-
fected patients. (b) The relatively short disease duration, as
Lunel et al. [52] showed that the duration of the disease in
HCV patients with MCG was almost twice as long than in
patients without MCG and (c) relatively younger age of our
patients, which agrees with some studies where it was noted
that patients with MCG were of older age while sex was not
a risk factor [58,59].
All of our CG+ patients had PN (10 clinical, 2 subclinical).
None of them showed clinical manifestations of MCG. This
agrees with the authors stating that HCV related PN is usuallyassociated with CG [10,11,19,36,39] and that the presence of
serum CGs is predictive of more severe and widespread neuro-
pathic involvement [12,60] and alsowith those who clariﬁed that
the only 13–30% of patients with CG are symptomatic [61].
Our patients showed signiﬁcantly higher levels of anti-neu-
ronal antibodies which were associated with electrophysiologi-
cal abnormalities in 50 out of the 54 neuropathic patients. This
ﬁnding is in keeping with Alpa et al. [62] who reported high
plasma IgM and IgG anti-GM1 titers in MCG patients, and
61% of patients having abnormal titers were associated with
clinical or subclinical evidence of neuropathy. Moreover, Ortiz
et al. [63] concluded that high IgM anti ganglioside titers are in-
volved in the etiopathogenesis of demyelinating neuropathies.
Statistical analysis showed a strong correlation between the
presence of PN and age of patients, disease duration, load of
viraemia, ESR, CRP, RF, IgM & IgG anti-GM1 and the pres-
ence of CGs. In addition; there was signiﬁcant negative corre-
lation between PN and C4 levels. On the other hand, no
signiﬁcant correlation could be found between PN and ANA,
staging of liver ﬁbrosis either by ultrasound scoring system or
modiﬁed Knodells score.
These results are in keeping with Zaltron et al. [39] who re-
ported a strong correlation between old age and PN although it
was unrelated to cryocrit levels or type of CG, and with higher
RF and reduced C4 activity, and with Santoro et al. [13] who
demonstrated that electrophysiological evidence of PN was sig-
niﬁcantly associated with older age and virus load, but not with
disease duration or CG. Also with Nemni et al. [12] who found
that HCV-related neuropathy was signiﬁcantly associated with
diminished serum C4 levels. Nevertheless, Lidove et al. [60], re-
ported that RF was always negative and C4 complement level
was always normal among their HCV patients.
The signiﬁcant relation between PN and virus load sup-
ports the mechanism which denotes that HCV may have a
direct role in the pathogenesis of neuropathy. Furthermore,
it support the immune hypothesis for the pathogenesis of PN
as evidenced by the correlation between electrophysiological
study and RF & diminished C4, which is in accordance with
Sterling and Bralow [32], who found that RF is often positive
in chronic HCV.
In conclusion, our ﬁndings demonstrate that PN exists in
high prevalence among Egyptian HCV patients, and is com-
monly associated with CG. It is mainly of axonal sensory type
with more affection of lower limbs. PN was found to correlate
with the age of the patients, disease duration, ESR, CRP, RF,
HCV viraemia, IgM and IgG anti-GM1 and hypocomplemen-
tinemia. It is recommended that HCV patients should be inves-
tigated for the presence of CGs even in the absence of clinical
manifestations suggestive of MCG. HCV patients with no clin-
ical evidence of neuropathy should be evaluated by electrodi-
agnosis, especially if they are CG+ve.
Conﬂict of interest
The authors have no conﬂict of interest.
References
[1] Lauer G, Walker BD. Hepatitis C virus infection. N Engl J Med
2001;345:41–52.
[2] Lagging M, Wejsta R, Uhnoo I, Gerde B, Fischler B, Friman S,
et al. Treatment of hepatitis C virus infection: updated Swedish
Consensus recommendations. Scand J Infect Dis 2009;4:389–402.
Prevalence of peripheral neuropathy in Egyptian hepatitis C virus patients 97[3] Zekri ARN, Bahnasy AA, Ramadan AS, El-Bassuoni M, Badran
A, Madwar MA. Hepatitis C virus genotyping versus serotyping
in Egyptian patients. Infection 2001;9(1):24–6.
[4] National Digestive Diseases Information Clearinghouse, National
Institute of Diabetes and Digestive and Kidney Diseases. Chronic
Hepatitis C: Current Disease Management. <http://www.diges-
tive.niddk.nih.gov/ddisease5/pubs/chronichepc>; [accessed May
22. 2008].
[5] Galossi A, Guarisco R, Bellis L, Puoti C. Extrahepatic manifes-
tations of chronic HCV infection. J Gastrointest Liver Dis
2007;16:65–73.
[6] Cacoub P, Sbai A, Hausfater P, Papo T, Gatel A, Piette JC.
Central nervous system involvement in hepatitis C virus infection.
Gastroenterol Clin Biol 1998;22:631–3.
[7] Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-
Ratti V, et al. Extrahepatic manifestations associated with
hepatitis C virus infection. A prospective multicenter study of
321 patients. The GERMIVIC. Groupe d’Etude et de Recherche
en Medecine Interne et Maladies Infectieuses sur le Virus de
l’Hepatite C. Medicine (Baltimore) 2000;79(1):47–56.
[8] Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC,
et al. Extrahepatic manifestations of chronic hepatitis C. MUL-
TIVIRC Group. Multidepartment Virus C. Arthritis Rheum
1999;42:2204–12.
[9] Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P,
et al. Mixed cryoglobulinemia: clinical aspects and long term
follow-up of 40 patients. Am J Med 1980;69:287–308.
[10] Cacoub P, Saadoun D, Limal N, Le´ger JM, Maisonobe T.
Hepatitis C virus infection and mixed cryoglobulinaemia vascu-
litis: a review of neurological complications. AIDS 2005;19(Suppl.
):S128–34.
[11] Authier FJ, Bassez G, Payan C, Guillevin L, Pawlotsky JM,
Degos JD, et al. Detection of genomic viral RNA in nerve and
muscle of patients with HCV neuropathy. Neurology
2003;60(5):808–12.
[12] Nemni R, Sanvito L, Quattrini A, Santuccio G, Camerlingo M,
Canal N. Peripheral neuropathy in hepatitis C virus infection with
and without cryoglobulinaemia. J Neurol Neurosurg Psychiatry
2003;74:1267–71.
[13] Santoro L, Manganelli F, Briani C, Giannini F, Benedetti L,
Vitelli E, et al. HCV Peripheral Nerve Study Group. Prevalence
and characteristics of peripheral neuropathy in hepatitis C virus
population. J Neurol Neurosurg Psychiatry 2006;77:626–9.
[14] Alpa M, Ferrero B, Cavallo R, Naretto C, Menegatti E, Di
Simone D, et al. Anti-neuronal antibodies in patients with HCV-
related mixed cryoglobulinemia. Autoimmun Rev 2008;8(1):56–8.
[15] Volta U, DeGiorgio R, Granito A, Stanghellini V, Barbara G,
Avoni P, et al. Anti-ganglioside antibodies in Coeliac disease with
neurological disorders. Dig Liver Dis 2006;38:183–7.
[16] Simons K, Ikonen E. Functional rafts in cell membrane. Nature
1997;387:569–72.
[17] Tembl JI, Ferrer JM, Sevilla MT, Lago A, Mayordomo F, Vilchez
JJ. Neurologic complications associated with hepatitis C virus
infection. Neurology 1999;53:861–4.
[18] Cacoub P, Maisonobe T, Thibault V, Gatel A, Servan J, Musset
L, et al. Systemic vasculitis in patients with hepatitis C. J
Rheumatol 2001;28(1):109–18.
[19] El Ghoneimy AT, Hasanien A, Ramzy GM, Youssof A, Elsayed
M, Shalaby NM, et al. Hepatitis C virus and peripheral neuro-
logical complications in Egyptian patients. Arab J Gastroenterol
2009;10:82–6.
[20] Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score
for identifying pain of predominately neuropathic origin: valida-
tion for use in clinical and postal research. J Pain 2005;6:149–58.
[21] Vermeersch P, Gijbels K, Marie¨n G, Lunn R, Egner W, White P,
et al. A critical appraisal of current practice in the detection,
analysis, and reporting of cryoglobulins. Clin Chem 2008;54:
39–43.[22] Pawlotsky JM. Use and interpretation of virological tests for
hepatitis C. Hepatology 2002;36, S65-73.
[23] Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J,
Dhumeaux D. Standardization of hepatitis C virus RNA quan-
tiﬁcation. Hepatology 2000;32:654–9.
[24] Pestronk A. Motor neuropathies, motor neuron disorders and
anti-glycolipid antibodies. Muscle Nerve 1991;14:927–36.
[25] Isoardo G, Ferrero B, Barbero P, Cucci A, Oggero A, Pipieri A,
et al. Anti-GM1 and anti-sulfatide antibodies in polyneuropa-
thies. Threshold titers and accuracy. Acta Neurol Scand
2001;103(3):180–7.
[26] Hung CH, Lu SN, Wang JH, Lee CM, Chen TM, Tung HD,
et al. Correlation between ultrasonographic and pathologic
diagnoses of hepatitis B and C-related cirrhosis. J Gastroenterol
2003;38(2):153–7.
[27] Brunt EM. Grading and staging the histopathological lesions of
chronic hepatitis: the Knodell histology activity index and
beyond. Hepatology 2000;31:241–6.
[28] Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur
RR, Magder LS, et al. The role of parenteral anti-schistosomal
therapy in the spread of hepatitis C virus in Egypt. Lancet
2000;355(9207):887–91.
[29] Villanova M, Caudai C, Sabatelli P, Toti P, Malandrini A, Luzi P,
et al. Hepatitis C virus infection and myositis: a polymerase chain
reaction study. Acta Neuropathol 2000;99(3):271–6.
[30] Nobile-Orazio E, Gallia F, Terenghi F, Allaria S, Giannotta C,
Carpo M. How useful are anti-neural IgM antibodies in the
diagnosis of chronic immune-mediated neuropathies? J Neurol Sci
2008;266:156–63.
[31] Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-
Hamid M, Gamil F, et al. Hepatitis C virus infection in a
community in the Nile Delta: risk factors for sero-positivity.
Hepatology 2001;33:248–53.
[32] Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C
virus. Curr Gastroenterol Rep 2006;8:53–9.
[33] Abul Hassan M, Hazem M, Albayomy Y, Sharaf Eldeen OA,
Zalata KR. Clinical relevance of cryoglobulinaemia and extrahe-
patic neurocutaneous manifestations of chronic hepatitis C. Egypt
J Neurol Psychiat Neurosurg 2008;45(1):117–27.
[34] Abo AL-Soud A, Ellehleh A, El-Kapany R, El-Hagary H. Study
of peripheral neuropathy in chronic hepatitis C virus infected
patients. J Am Sci 2011;7(4):282–8.
[35] Gomes I, Nora DB, Marquezini NC, Said G, Melo A. Peripheral
neuropathy in patients with hepatitis virus C infection in the
Amazon region. Arq Neuro-Psiquiatr 2006;64:600–2.
[36] Ripault MP, Borderie C, Dumas P, Vallat JM, Goujon JM,
Brecheteau P, et al. Peripheral neuropathies and chronic hepatitis
C: a frequent association? Gastroenterol Clin Biol 1998;22:891–6.
[37] England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK,
Carter GT, et al. Distal symmetrical polyneuropathy: a deﬁnition
for clinical research. A report of the American Academy of
Neurology, the American Association of Electrodiagnostic Med-
icine, and the American Academy of Physical Medicine and
Rehabilitation. Arch Phys Med Rehabil 2005;86(1):167–74.
[38] Yoon MS, Obermann M, Dockweiler C, Assert R, Canbay A,
Haag S, et al. Sensory neuropathy in patients with cryoglobulin
negative hepatitis C infection. J Neurol 2011;258:80–8.
[39] Zaltron S, Puoti M, Liberini P, Antonin L, Quinzanini M, Manni
M, et al. High prevalence of peripheral neuropathy in hepatitis C
virus infected patients with symptomatic and asymptomatic
cryoglobulinaemia. Ital J Gastroenterol Hepatol
1998;30(4):391–5.
[40] Taieb G, Maisonobe T, Musset L, Cacoub P, Leger JM, Bouche
P. Cryoglobulinemic peripheral neuropathy in hepatitis C virus
infection: clinical and anatomical correlations of 22 cases. Rev
Neurol (Paris) 2010;166(5):509–14.
[41] Acharya JN, Pacheco VH. Neurologic complications of hepatitis
C. Neurologist 2008;14:151–6.
98 M. Aly Abdel Khalek et al.[42] Boukhrisa S, Magya L, Senga-mokonoa U, Loustaud-rattib V,
Vallata J-M. Polyneuropathy with demyelinating features in
mixed cryoglobulinemia with hepatitis C virus infection. Eur J
Neurol 2006;13:937–41.
[43] Morgello S. The nervous system and hepatitis C virus. Semin
Liver Dis 2005;25:118–21.
[44] Ammendola A, Sampaolo S, Ambrosone L, Ammendola E,
Ciccone G, Migliaresi S, et al. Peripheral neuropathy in hepatitis-
related mixed cryoglobulinemia: electrophysiologic follow-up
study. Muscle Nerve 2005;31:382–5.
[45] Chin RL, Sander HW, Brannagan TH, De Sousa E, Latov N.
Demyelinating neuropathy in patients with hepatitis C virus
infection. J Clin Neuromuscular Dis 2010;11(4):209–21.
[46] Mestre TA, Correia de Sa´ J, Pimentel J. Multifocal central and
peripheral demyelination associated with hepatitis C virus infec-
tion. J Neurol 2007;254:1754–6.
[47] Corcia P, Barbereau D, Guennoc AM, de Toffol B, Bacq Y.
Improvement of a CIDP associated with hepatitis C virus
infection using antiviral therapy. Neurology 2004;63:179–80.
[48] Oberbeek BU, van Alfen N, Bor JA, Zwarts MJ. Sural/Radial
nerve amplitude ratio: reference values in healthy subjects. Muscle
Nerve 2005;32:613–8.
[49] Kim KT, Park K, Ko H. Sensitivity of electrodiagnostic param-
eters in patients with asymptomatic diabetic neuropathy. J
Korean Acad Rehabil Med 2003;27:75–9.
[50] Rutkove SB, Kothari MJ, Raynor EM, Levy ML, Fadic R,
Nardin RA. Sural/radial amplitude ratio in the diagnosis of mild
axonal polyneuropathy. Muscle Nerve 1997;20:1236–41.
[51] Gad A, Tanaka E, Matsumoto A, Serwah A, Ali K, Makledy F,
et al. Factors predisposing to the occurrence of cryoglobulinemia
in two cohorts of Egyptian and Japanese patients with chronic
hepatitis C infection: ethnic and genotypic inﬂuence. J Med Virol
2003;70(4):594–9.
[52] Lunel M, Musset L, Cacoub P, Frangeul L, Cresta P, Perrin M,
et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis
C virus and liver damage. Gastroenterology 1994;106:1291–300.
[53] Wong VS, Egner W, Elsey T, Brown D, Alexander GJ. Incidence,
character and clinical relevance of mixed cryoglobulinemia in
patients with chronic hepatitis C virus infection. Clin Exp
Immunol 1996;104:25–31.[54] Zarebska-Michaluk DA, Lebensztejn DM, Kryczka WM, Skiba
E. Extrahepatic manifestations associated with chronic hepatitis C
infections in Poland. Adv Med Sci 2010;55:67–73.
[55] Liakina V, Speiciene D, Irnius A, Naraskeviciene J, Barakauski-
ene A, Semuchiniene T. Prevalence of cryoglobulinemia in
patients with chronic HCV infection. Med Sci Monit
2002;8(1):CR31–6.
[56] Persico M, De Marino FA, Russo GDG, Persico E, Morante A,
Palmentieri B, et al. Prevalence and incidence of cryoglobulins in
hepatitis C virus-related chronic hepatitis patients: a prospective
study. Am J Gastroenterol 2003;98:884–8.
[57] Verbaan H, Carlson J, Eriksson S, Larsson A, Liedholm R,
Manthorpe R, et al. Extrahepatic manifestations of chronic
hepatitis C infection and the interrelationship between primary
Sjo¨gren’s syndrome and hepatitis C in Swedish patients. J Intern
Med 1999;245(2):127–32.
[58] Akriviadis E, Xanthakis I, Navrozidou C, Papadopoulos A.
Prevalence of cryoglobulinemia in chronic hepatitis C virus
infection and response to treatment with interferon-alpha. J Clin
Gastroenterol 1997;25:612–8.
[59] Perniola R, De Rinaldis C, Accogli E, Lobreglio G. Prevalence
and clinical features of cryoglobulinaemia in multitransfused beta-
thalassaemia patients. Ann Rheum Dis 1999;58:698–702.
[60] Lidove O, Cacoub P, Maisonobe T, Servan J, Thibault V, Piette
JC, et al. Hepatitis C virus infection with peripheral neuropathy is
not always associated with cryoglobulinaemia. Ann Rheum Dis
2001;60:290–2.
[61] Vigani AG, Macedo-de-Oliveira A, Pavan MHP, Pedro MN,
Gonc¸ales Jr FL. Hepatitis C virus infection, cryoglobulinemia,
and peripheral neuropathy: a case report. Braz J Med Biol Res
2005;38(12):1729–34.
[62] Alpa M, Ferrero B, Cavallo R, Naretto C, Gennaro M, Bellizia L,
et al. Anti-GM1 and anti-sulphatide antibodies in systemic
idiopathic vasculitis, systemic lupus erythematosus and mixed
cryoglobulinaemia: serum detection and clinical and electrophys-
iologic correlations. G Ital Nefrol 2002;19(6):617–21.
[63] Ortiz N, Sabate´ MM, Garcia N, Santafe MN, Lanuza MA,
Toma`s M, et al. Effect of anti-GM2 antibodies on rat sciatic
nerve: electrophysiological and morphological study. J Neuroim-
munol 2009;208:61–9.
